Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a prevalent genetic disorder leading to premature cardiovascular disease (CVD).
• Significant variations in reported prevalence rates for heterozygous FH (HeFH) and homozygous FH (HoFH) exist, largely due to inconsistent diagnostic criteria globally.
• The need for unified guidelines and global registries is critical for advancing FH knowledge and patient care.

Purpose of the Study:

• To provide a comprehensive review of Familial hypercholesterolemia.
• To summarize current understanding of FH pathophysiology, epidemiology, clinical manifestations, and pharmacological treatments.
• To present updated recommendations and guidelines for FH management.

Main Methods:

• Literature review of existing studies on FH.
• Synthesis of data on FH pathophysiology and epidemiology.
• Compilation of current pharmacological treatment options and clinical guidelines.

Main Results:

• FH is a significant genetic risk factor for early-onset CVD.
• Inconsistent diagnostic criteria contribute to variable prevalence data for HeFH and HoFH.
• Current research indicates promising novel therapies for FH with potential for improved lipid-lowering and reduced side effects.

Conclusions:

• Standardizing diagnostic criteria and establishing global registries are essential for accurate FH prevalence assessment and improved patient outcomes.
• Updated guidelines and ongoing research into novel therapies are crucial for advancing FH treatment.
• Future FH therapies aim for enhanced efficacy, better safety profiles, and improved clinical results.